Figure 1.
Treatment exposure, duration of response (as assessed per RECIST version 1.1 per central review), and overall survival time in individual patients. Bar lengths indicate time from start of first treatment to death or last follow‐up. ALK, anaplastic lymphoma kinase translocation; EGFRm, epidermal growth factor receptor mutant; PD, progressive disease; PD‐L1, programmed death ligand 1; PR, partial response; RECIST, Response Evaluation Criteria in Solid Tumors; TPS, tumor proportion score